

10764229

necting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAH1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:46:38 ON 14 DEC 2005

10764229

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:46:49 ON 14 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2005 HIGHEST RN 869843-02-7
DICTIONARY FILE UPDATES: 13 DEC 2005 HIGHEST RN 869843-02-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10764229.str

L1 STRUCTURE UPLOADED

=> s l1 sam

SAMPLE SEARCH INITIATED 10:47:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 286 TO 954

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

10764229

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.43

0.64

FILE 'CAPLUS' ENTERED AT 10:47:18 ON 14 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Dec 2005 VOL 143 ISS 25

FILE LAST UPDATED: 13 Dec 2005 (20051213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:47:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 667 TO ITERATE

100.0% PROCESSED 667 ITERATIONS

167 ANSWERS

SEARCH TIME: 00.00.01

L3 167 SEA SSS FUL L1

L4 7 L3

=> d ibib abs hitstr total

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:510348 CAPLUS


DOCUMENT NUMBER: 143:193927

TITLE: Practical application of new catalytic methods: a concise synthesis of a potent PDE IV inhibitor

AUTHOR(S): Albaneze-Walker, Jennifer; Murry, Jerry A.; Soheili, Arash; Ceglia, Scott; Springfield, Shawn A.; Bazaral,

10764229

CORPORATE SOURCE: Charles; Dormer, Peter G.; Hughes, David L.
Process Research, Merck Research Laboratories, Merck
and Co., Inc., Rahway, NJ, 07065, USA
SOURCE: Tetrahedron (2005), 61(26), 6330-6336
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:193927
GI



AB An efficient synthesis of a potent PDE IV inhibitor I is described. The synthesis is highlighted by two practical and efficient catalytic reactions: a highly selective catalytic palladium mediated carbonylation of the pyridine side chain and an efficient palladium-catalyzed Suzuki-Miyaura coupling of a chloropyridine-N-oxide.


IT **477252-51-0P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(scalable preparation of (cyclopropylcarbamoyl)(oxidopyridylphenyl)naphthyri done as PDE IV inhibitor using regioselective carbonylation and Suzuki-Miyaura cross-coupling as key steps)

RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



10764229

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1059128 CAPLUS

DOCUMENT NUMBER: 142:32997

TITLE: Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders

INVENTOR(S): Scolnick, Edward M.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004105698 | A2 | 20041209 | WO 2004-US16492 | 20040525 |
| WO 2004105698 | A3 | 20050602 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.: US 2003-474168P P 20030529

AB The use of a phosphatase inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder. The phosphatase that is inhibited can be calcineurin or protein phosphatase 1. Treatment with a phosphatase inhibitor can be combined with a phosphodiesterase 4 inhibitor.

IT **701263-25-4P**, N-Cyclopropyl-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,4-dihydro-1,8-naphthyridine-3-carboxamide
702640-57-1P 702640-64-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; use of phosphatase inhibitors such calcineurin and protein phosphatase 1 as adjunct therapy for psychiatric disorders combined with phosphodiesterase 4 inhibitors)

RN 701263-25-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)


10764229



RN 702640-57-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702640-64-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **702639-56-3P**, 2-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]-2-methylpropanoic acid
702639-58-5P 702639-59-6P 702639-63-2P,
 2-trans-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid
702639-69-8P, 2-trans-[3-Chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid
702639-71-2P, 2-cis-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid
702639-90-5P,
 (+)-trans-2-[3-Fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid
702639-91-6P 702639-93-8P, trans-2-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]-2-methylcyclopropanecarboxylic acid
702639-95-0P,
 2-trans-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-1,1'-biphenyl-4-yl]cyclopropanecarboxylic acid
702639-96-1P,
 3-Methyl-3-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]butanoic acid
702639-98-3P
702640-04-8P, (+)-trans-2-[3-Chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid
702640-06-0P,
 (-)-trans-2-[3'-[4-Oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]cyclopropanecarboxylic acid
702640-13-9P, 3-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]-2,2-dimethylpropanoic acid
702640-28-6P, 4-[3'-[3-[(Cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]-3,3-dimethylbutanoic acid
702640-30-0P, 1-[[3'-[4-Oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]methyl]cyclobutanecarboxylic acid
702640-35-5P,
 2,2-Dimethyl-4-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]biphenyl-4-yl]butanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(use of phosphatase inhibitors such calcineurin and protein phosphatase 1 as adjunct therapy for psychiatric disorders combined with

10764229

phosphodiesterase 4 inhibitors)


RN 702639-56-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- β,β -dimethyl- (9CI) (CA INDEX NAME)



RN 702639-58-5 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 702639-59-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-63-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-69-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-71-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-90-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.

10764229



RN 702639-91-6 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 702639-93-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2-methyl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-95-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702639-96-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[4-oxo-3-[[(2,2,2-trifluoroethyl) amino] carbonyl]-1,8-naphthyridin-1(4H)-yl]- (9CI) (CA INDEX NAME)


10764229



RN 702639-98-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702640-04-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


10764229



RN 702640-06-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl-, (1R,2R)-rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 702640-13-9 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

10764229




RN 702640-28-6 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-β,β-dimethyl- (9CI) (CA INDEX NAME)




RN 702640-30-0 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 702640-35-5 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, α,α-dimethyl-3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:467891 CAPLUS

DOCUMENT NUMBER: 141:38597

TITLE: Preparation of aryl substituted 1,8-naphthyridin-4(1H)-ones as inhibitors of phosphodiesterase-4

INVENTOR(S): Albaneze-Walker, Jennifer; Murry, Jerry Anthony; Soheili, Arash; Springfield, Shawn A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|------------------|-----------------|------------|
| WO 2004048377 | A2 | 20040610 | WO 2003-US36806 | 20031118 |
| WO 2004048377 | A3 | 20040902 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2506656 | AA | 20040610 | CA 2003-2506656 | 20031118 |
| EP 1565466 | A2 | 20050824 | EP 2003-783636 | 20031118 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003016464 | A | 20051011 | BR 2003-16464 | 20031118 |
| NO 2005003047 | A | 20050810 | NO 2005-3047 | 20050621 |
| PRIORITY APPLN. INFO.: | | | US 2002-428315P | P 20021122 |
| | | | US 2003-472655P | P 20030522 |
| | | | WO 2003-US36806 | W 20031118 |
| OTHER SOURCE(S): | | MARPAT 141:38597 | | |
| GI | | | | |

AB In one aspect, the present invention is directed to a one pot method of preparing intermediates I [OR1 = a suitable leaving group; R3 = (un)substituted alkyl, aryl, heteroaryl], which are useful in making inhibitors of phosphodiesterase-4. The present invention is also directed to a method of preparing phosphodiesterase inhibitors (no biol. data given) comprising the compds. II and III which comprises reacting IV [OR1 as above] with a 3-bromopyridine-N-oxide.HCl or 3-bromopyridine in the presence of a palladium catalyst and a phosphine ligand in amine base followed by reaction of the resulting V or VI with cyclopropylamine, optionally in the presence of catalyst. Thus, reacting IV [R1 = Et] with a 3-bromopyridine-N-oxide.HCl in the presence of [(allyl)PdCl]₂, P(tert-Bu)₃, tert-amylamine in DMAc followed by reacting V [R1 = Et] with cyclopropylamine afforded II. Preparation of 77 aryl substituted 1,8-naphthyridin-4(1H)-ones and their intermediates is also described.


IT 477251-83-5P 477251-87-9P 477251-92-6P
 477251-93-7P 477251-95-9P 477251-97-1P
 477251-99-3P 477252-00-9P 477252-01-0P
 477252-05-4P 477252-08-7P 477252-09-8P
 477252-11-2P 477252-23-6P 477252-25-8P
 477252-26-9P 477252-31-6P 477252-32-7P
 477252-36-1P 477252-43-0P 694489-52-6P
 701977-61-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aryl substituted 1,8-naphthyridin-4(1H)-ones as inhibitors of phosphodiesterase-4)

RN 477251-83-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-87-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477251-92-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 477251-93-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyne)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-95-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-99-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-00-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-05-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-08-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-09-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-11-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-23-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-26-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 477252-31-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-32-7 . CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-36-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-43-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 694489-52-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 701977-61-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[3-[[[1-methylethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 477251-76-6P 477251-82-4P 477251-84-6P
 477251-85-7P 477251-88-0P 477251-89-1P
 477251-94-8P 477252-02-1P 477252-03-2P
 477252-04-3P 477252-06-5P 477252-10-1P
 477252-12-3P 477252-13-4P 477252-14-5P
 477252-15-6P 477252-16-7P 477252-17-8P
 477252-21-4P 477252-22-5P 477252-24-7P
 477252-27-0P 477252-28-1P 477252-30-5P
 477252-33-8P 477252-34-9P 477252-35-0P
 477252-37-2P 477252-38-3P 477252-39-4P
 477252-40-7P 477252-41-8P 477252-44-1P
 477252-46-3P 477252-47-4P 477252-48-5P
 477252-49-6P 477252-50-9P 477252-51-0P
 477252-53-2P 477252-54-3P 477252-55-4P
 477252-56-5P 477252-57-6P 477252-58-7P
 477252-59-8P 477252-60-1P 477252-61-2P
 477252-62-3P 477252-63-4P 477252-64-5P
 477252-65-6P 694489-50-4P 694489-58-2P
 701977-62-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aryl substituted 1,8-naphthyridin-4(1H)-ones as inhibitors
 of phosphodiesterase-4)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
 dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-82-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-
 propyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)



10764229


RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-88-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-89-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-02-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-03-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-06-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-10-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-12-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-13-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-{6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl}phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




| | |
|----|---|
| CN | 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME) |
|----|---|




CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-22-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-24-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-27-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-28-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-30-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-34-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-35-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-37-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-38-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-39-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-41-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methylsulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-44-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 477252-47-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477252-48-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-50-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-51-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-54-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-55-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 477252-56-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-57-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI)
(CA INDEX NAME)

10764229




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-


10764229

1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-62-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-63-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-64-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-65-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 694489-50-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 694489-58-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 701977-62-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(1,6-dihydro-6-oxo-3-pyridinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:467889 CAPLUS

DOCUMENT NUMBER: 141:38596



TITLE: Preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors

INVENTOR(S): Dube, Daniel; Gallant, Michel; Lacombe, Patrick; Aspiotis, Renee; Dube, Laurence; Girard, Yves;

10764229

PATENT ASSIGNEE(S): MacDonald, Dwight
 SOURCE: Merck Frosst Canada & Co., Can.
 PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2004048374 | A1 | 20040610 | WO 2003-CA1800 | 20031119 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2506648 | AA | 20040610 | CA 2003-2506648 | 20031119 |
| EP 1565464 | A1 | 20050824 | EP 2003-775029 | 20031119 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| BR 2003016458 | A | 20051011 | BR 2003-16458 | 20031119 |
| US 2005107402 | A1 | 20050519 | US 2004-764229 | 20040123 |
| NO 2005003046 | A | 20050727 | NO 2005-3046 | 20050621 |
| PRIORITY APPLN. INFO.: | | | US 2002-428611P | P 20021122 |
| | | | WO 2003-CA1800 | W 20031119 |
| OTHER SOURCE(S): | MARPAT 141:38596 | | | |
| GI | | | | |



AB Title compds. [I; Ar = Ph, pyridyl, pyrimidyl, indolyl, quinolyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl; Y = CO₂R₄, ACO₂R₄, etc.; A = alkyl; R, R₄ = H, alkyl; R₁ = H, (substituted) alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, heteroaryl, heterocyclyl; R₂ = H, halo, cyano, NO₂, (substituted) alkyl, cycloalkyl, alkoxy, Ph, heteroaryl,

10764229

amino, etc.; R3 = H, halo, cyano, NO2, (substituted) alkyl, cycloalkyl, etc.], were prepared Thus, title compound (II) (preparation outlined) inhibited

PDE4-mediated hydrolysis of cAMP to AMP with IC50 = 0.1 nM.

IT 702639-52-9P 702639-53-0P 702639-54-1P
702639-55-2P 702639-56-3P 702639-57-4P
702639-58-5P 702639-59-6P 702639-60-9P
702639-61-0P 702639-62-1P 702639-63-2P
702639-64-3P 702639-65-4P 702639-66-5P
702639-67-6P 702639-69-8P 702639-71-2P
702639-73-4P 702639-74-5P 702639-76-7P
702639-78-9P 702639-80-3P 702639-81-4P
702639-83-6P 702639-85-8P 702639-86-9P
702639-88-1P 702639-90-5P 702639-91-6P
702639-93-8P 702639-95-0P 702639-96-1P
702639-98-3P 702640-00-4P 702640-02-6P
702640-04-8P 702640-06-0P 702640-08-2P
702640-10-6P 702640-12-8P 702640-13-9P
702640-15-1P 702640-16-2P 702640-17-3P
702640-18-4P 702640-19-5P 702640-20-8P
702640-21-9P 702640-22-0P 702640-23-1P
702640-24-2P 702640-25-3P 702640-26-4P
702640-27-5P 702640-28-6P 702640-29-7P
702640-30-0P 702640-31-1P 702640-32-2P
702640-33-3P 702640-34-4P 702640-35-5P
702640-36-6P 702640-37-7P 702640-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors)

RN 702639-52-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10764229

RN 702639-53-0 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 702639-54-1 CAPLUS

CN [1,1'-Biphenyl]-3-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 702639-55-2 CAPLUS


CN [1,1'-Biphenyl]-4-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)

CC(C)(C(=O)O)c1ccc2cc3c(cc12)c4ccc5c3c(=O)c(=O)n5c4n6ccc7c(=O)nc(NC8CC8)c76

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- β,β -dimethyl- (9CI) (CA INDEX NAME)




CN [1,1'-Biphenyl]-4-acetic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α -hydroxy- (9CI) (CA INDEX NAME)



CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


10764229



RN 702639-59-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702639-60-9 CAPLUS


CN 1,3-Dioxolane-4-carboxylic acid, 5-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

10764229




RN 702639-61-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 702639-62-1 CAPLUS

CN Cyclopropanecarboxylic acid, 1-cyano-3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 702639-63-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-64-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-65-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-bromo-5'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-66-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-methyl[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-67-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-2-methyl[1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-69-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-71-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10764229



RN 702639-73-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- (9CI) (CA INDEX NAME)




RN 702639-74-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-(4-morpholinylcarbonyl)-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-76-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-78-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methylthio)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-80-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methylsulfonyl)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-81-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-83-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[5-[3-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-2-thienyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702639-85-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[(cyclopropylmethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702639-86-9 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[1-(1-cyanocyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702639-88-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[3-[[1-(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- (9CI) (CA INDEX NAME)


10764229



RN 702639-90-5 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702639-91-6 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 702639-93-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-

10764229

1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2-methyl-, (1R,2R)-rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702639-95-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-
1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 702639-96-1 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, β,β -dimethyl-3'-[4-oxo-3-
[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (9CI)
(CA INDEX NAME)


10764229



RN 702639-98-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-2-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702640-00-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,3,3,3-pentafluoropropyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702640-02-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-1-fluoro-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702640-04-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


10764229



RN 702640-06-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




RN 702640-08-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


10764229



RN 702640-10-6 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1-methylethyl ester, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-12-8 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10764229




RN 702640-13-9 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)



RN 702640-15-1 CAPLUS


CN [1,1'-Biphenyl]-3-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)



RN 702640-16-2 CAPLUS


CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-3-yl]methyl]- (9CI) (CA INDEX NAME)

10764229




RN 702640-17-3 CAPLUS

CN [1,1'-Biphenyl]-2-propanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)



RN 702640-18-4 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-[1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 702640-19-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(1,1-dimethylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)

10764229

4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)-
(9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-20-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclobutylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI)
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-21-9 CAPLUS


CN Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

10764229



RN 702640-22-0 CAPLUS


CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-γ-hydroxy-γ-methyl- (9CI) (CA INDEX NAME)



RN 702640-23-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 702640-24-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[(dicyclopropylmethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

10764229


1]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-,
(1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-25-3 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 702640-26-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(1-hydroxycyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


10764229



RN 702640-27-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[1-phenylcyclopropyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-28-6 CAPLUS

CN [1,1'-Biphenyl]-4-butanoic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-β,β-dimethyl- (9CI) (CA INDEX NAME)


10764229



RN 702640-29-7 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[1-cyclopropyl-1-methylethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)-(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-30-0 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 702640-31-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylmethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)-(9CI)

10764229

(9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-32-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[3-[[1-hydroxycyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




RN 702640-33-3 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[2,2,2-trifluoro-1-methylethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702640-34-4 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(1-methylcyclopropyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 702640-35-5 CAPLUS


CN [1,1'-Biphenyl]-4-butanoic acid, α,α-dimethyl-3'-[4-oxo-3-[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (9CI) (CA INDEX NAME)

10764229



RN 702640-36-6 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, α,α -dimethyl-3'-[4-oxo-3-[[2,2,2-trifluoroethyl]amino]carbonyl]-1,8-naphthyridin-1(4H)-yl]- (9CI)
(CA INDEX NAME)



RN 702640-37-7 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-chloro-3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




10764229

RN 702640-38-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[4-oxo-3-[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 702640-46-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors)

RN 702640-46-8 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[(2,2,2-trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, (1R,2R)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 701263-25-4 702640-57-1 702640-59-3

10764229


702640-62-8 702640-64-0 702640-66-2
702640-70-8 702640-74-2 702640-76-4
702640-77-5 702640-79-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of biphenylnaphthyridonecarboxamides as phosphodiesterase-4 inhibitors)

RN 701263-25-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 702640-57-1 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702640-59-3 CAPLUS


CN 1,3-Dioxolane-4-carboxylic acid, 5-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

10764229



RN 702640-62-8 CAPLUS

CN Cyclopropanecarboxylic acid, 1-cyano-3-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-2,2-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 702640-64-0 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10764229



RN 702640-66-2 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3'-bromo-5'-[3-
[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-
biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 702640-70-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[3-[(cyclopropylamino)carbonyl]-4-
oxo-1,8-naphthyridin-1(4H)-yl]-, ethyl ester (9CI) (CA INDEX NAME)


10764229



RN 702640-74-2 CAPLUS


CN Cyclopropanecarboxylic acid, 2-[3'-[3-[[[2-(methylthio)ethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 702640-76-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 702640-77-5 CAPLUS

CN Cyclopropanecarboxylic acid, 2-[3-fluoro-3'-[4-oxo-3-[[2,2,2-

10764229


trifluoroethyl)amino]carbonyl]-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, methyl ester, (1R,2R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 702640-79-7 CAPLUS

CN Cyclobutanecarboxylic acid, 1-[[3'-[3-[(cyclopropylamino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:467741 CAPLUS

DOCUMENT NUMBER: 141:38595

TITLE: Preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as enhancers of cognition


INVENTOR(S): Dube, Daniel; Gallant, Michel; Lacombe, Patrick; Girard, Yves; MacDonald, Dwight; Friesen, Richard; Ducharme, Yves; Cote, Bernard; Blouin, Marc; Martins, Evelyn; Guay, Daniel; Girard, Mario; Frenette, Richard; Laliberte, Sebastien; Robichaud, Annette; Mastracchio, Anthony; Perrier, Helene

10764229

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.; Hamel, Pierre
 SOURCE: PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2004047836 | A1 | 20040610 | WO 2003-CA1799 | 20031119 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| EP 1592419 | A1 | 20051109 | EP 2003-776698 | 20031119 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRIORITY APPLN. INFO.: | | | US 2002-428541P | P 20021122 |
| | | | WO 2003-CA1799 | W 20031119 |

GI



AB Substituted naphthyridines are prepared as PDE-4 inhibitors. For instance, Et 3-(3-bromoanilino)-2-(2-chloronicotinoyl)acrylate (preparation given) is treated with NaH in THF to give Et 1-(3-bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxylate. This intermediate is saponified, coupled to i-PrNH₂ (THF, Et₃N, i-BuOCOC1) and coupled to 3-acetylphenylboronic acid (PhMe, EtOH, Na₂CO₃, trans-dibromobis(triphenylphosphine)palladium, reflux, 1 h) to give I. Example compds. have IC₅₀ values of 0.1 to 90.0 nM for PDE₄; these compds. are useful for enhancing memory, learning, retention, recall, awareness and judgement.

IT **477251-83-5P**, N-Isopropyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-87-9P**,


N-Isopropyl-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-91-5P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-92-6P 477251-93-7P**, N-Isopropyl-1-[3-(quinolin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-95-9P**, N-Cyclopropyl-1-[3-(pyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-97-1P**, N-Isopropyl-1-[3-[5-(methylsulfonyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-99-3P**, N-Cyclopropyl-1-[3-(4-hydroxymethylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-00-9P**, N-Cyclopropyl-1-[3-(pyridin-4-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-01-0P**, N-Cyclopropyl-1-[3-[4-(ethylsulfonyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-05-4P**, N-Isopropyl-1-[3-[4-(methylsulfonyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-07-6P**, N-Isopropyl-1-[3-(5-carboethoxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-08-7P**, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-09-8P**, N-Isopropyl-1-[3-[6-(2-methylpropyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-10-1P 477252-11-2P**, N-Isopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-23-6P**, N-Cyclopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-25-8P**, N-Cyclopropyl-1-[3-(5-bromopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-26-9P**, N-Cyclopropyl-1-[3-(6-benzoyloxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-31-6P**, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-32-7P**, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-35-0P**, N-Cyclopropyl-1-[3-(6-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-43-0P**, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as enhancers of cognition)

RN 477251-83-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 477251-91-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-92-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[[1-methylethyl]amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 477251-93-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477251-95-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-97-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-99-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-00-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-01-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-05-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-07-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 477252-08-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



•


1

1

2


1

10764229




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-26-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 477252-31-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

IT **477251-76-6P**, N-Isopropyl-1-[3-(3-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-80-2P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(3-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-82-4P** **477251-84-6P**, N-Isopropyl-1-[3-(2-methylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-85-7P**, N-Isopropyl-N-methyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-88-0P**, N-Isopropyl-1-[3-(indol-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-89-1P**, N-tert-Butyl-1-[3-(4-acetylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477251-94-8P**, N-Isopropyl-1-[3-(pyrimidin-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-02-1P**, N-Cyclopropyl-1-[3-(3-thienyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-03-2P**, N-Cyclopropyl-1-[3-(4-sulfamoylphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-04-3P**, N-Isopropyl-1-[3-(3-ethoxyphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-06-5P**, N-Isopropyl-1-[3-(3-acetyl-4-hydroxyphenyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-12-3P**, N-Cyclopropyl-1-[3-(1-oxidopyrimidin-5-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-13-4P**, 1-[3-[6-(1-Hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-14-5P** **477252-15-6P**, N-Cyclopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-16-7P**, N-Cyclopropyl-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-17-8P**, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-18-9P**, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)pyridin-4-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-19-0P**, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxidopyridin-4-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-21-4P**, N-Cyclopropyl-1-[3-(6-isopropylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-22-5P**, N-Cyclopropyl-1-[3-(6-methoxypyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide

477252-24-7P, N-Cyclopropyl-1-[3-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide
477252-27-0P, N-Cyclopropyl-1-[3-[6-(bis(cyclopropyl)(hydroxy)methyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-28-1P**, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-30-5P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-33-8P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-34-9P 477252-36-1P**, N-Isopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-37-2P**, N-Cyclopropyl-1-[3-[4-(ethylsulfonyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-38-3P**, N-Cyclopropyl-1-[3-[4-(ethylsulfinyl)phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-39-4P 477252-40-7P 477252-41-8P**, N-Cyclopropyl-1-[3-[4-[(methylsulfonyl)methyl]phenyl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-42-9P**, N-Cyclopropyl-1-[3-(1,6-dihydro-6-oxopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-44-1P**, N-Isopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-45-2P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-46-3P**, N-Isopropyl-1-[3-(5-carboethoxy-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-47-4P**, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-48-5P**, N-Isopropyl-1-[3-[6-(2-methylpropyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-49-6P**, N-Isopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-50-9P**, N-Cyclopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-51-0P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-53-2P**, N-Cyclopropyl-1-[3-(1-oxidopyridin-4-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-54-3P**, N-Cyclopropyl-1-[3-(5-bromo-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-55-4P**, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]pyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-57-6P**, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-58-7P**, N-Isopropyl-1-[3-(1-oxidoquinolin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-59-8P**, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-60-1P**, N-Cyclopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-61-2P**, N-Cyclopropyl-1-[3-(6-methylsulfonyl-1-oxidopyridin-3-yl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-62-3P**, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide **477252-63-4P**, N-Cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10764229

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of substituted naphthyridine phosphodiesterase-4 inhibitors as
enhancers of cognition)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477251-80-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(2,6-
dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-82-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-
propyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-


10764229

yl)-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477251-85-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-88-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-89-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-94-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-02-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-03-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-06-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-12-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-13-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-14-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-15-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-16-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-17-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-18-9 CAPLUS

CC(C)(O)c1ccc2c(c1)c3ccncc3n(c2)c4ccc(=O)c(=O)c4C(=O)NCC5CC5

RN 477252-19-0 CAPLUS

CN(C)C(=O)c1cnc2c(c1)c3ccccc3c2c4cc5c(nc6ccccc6n5)cc(=O)nc4C(=O)N7CC7


RN 477252-21-4 CAPLUS

CC(C)S(=O)(=O)c1ccc2c(c1)c3ccccc3n2C4=CC(=O)N(C5=CC=CC=C5)C(=O)C6=CC=CC=C6NC7CC7

10764229


RN 477252-22-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-24-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 477252-27-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-28-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-30-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-33-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-34-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-36-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-37-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-38-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-39-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-40-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-41-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methanesulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-42-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(1,6-dihydro-6-oxo-3-pyridinyl)phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-44-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-45-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 477252-47-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477252-48-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-50-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-51-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-53-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-54-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-55-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 477252-57-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

Cc1ccc(cc1)c2nc3c(nc(=O)c3c2C(=O)N)nc4ccccc4n1CN(C)C(=O)c1cnc2c(c1)cnc2-c1ccc(cc1)-c1ccc2c(c1)c(=O)[nH]c2C(C)CCc1ccccc1-c1ccc(cc1)-c2cc3c(cc2)c(=O)[nH]c3c4cccnc4C(=O)Nc5ccccc5


| | | |
|----|--|--------|
| RN | 477252-61-2 | CAPLUS |
| CN | 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME) | |

10764229




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-63-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:433770 CAPLUS

DOCUMENT NUMBER: 141:7041

TITLE: One-pot preparation of naphthyridine derivatives, useful as inhibitors of phosphodiesterase-4

INVENTOR(S): Albaneze-Walker, Jennifer; Ceglia, Scott; Murry, Jerry

10764229

PATENT ASSIGNEE(S): Anthony; Soheili, Arash
 SOURCE: Merck & Co., Inc., USA
 U.S. Pat. Appl. Publ., 57 pp., which
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|------------------------------------|-----------------|------------|
| US 2004102472 | A1 | 20040527 | US 2003-690118 | 20031021 |
| US 6909002 | B2 | 20050621 | | |
| PRIORITY APPLN. INFO.: | | | US 2002-428315P | P 20021122 |
| | | | US 2003-472598P | P 20030522 |
| OTHER SOURCE(S): | | CASREACT 141:7041; MARPAT 141:7041 | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to one-pot preparation of naphthyridine derivs. of formula I [wherein: OR1 is a suitable leaving group; R2 is C1-8alkyl, (un)substituted (hetero)aryl], useful as inhibitors of phosphodiesterase-4 (no biol. data). For instance, naphthyridine derivative II was prepared via heterocyclization of Et 2-chloronicotinoylacetate, 3-bromoaniline, and acetic anhydride, hydrolysis of the obtained ester III (R3 = Br), amidation by isopropylamine, and subsequent phenylacetylation by 3-acetylphenylboronic acid (example 1, no yield data). Naphthyridine derivative IV was prepared using the prepared intermediate III [R3 = -B(OH)2]

(p.

49-53).


IT **477252-05-4P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors of phosphodiesterase-4)

RN 477252-05-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



IT **477251-76-6P 477251-82-4P 477251-83-5P**
477251-84-6P 477251-85-7P 477251-87-9P
477251-88-0P 477251-89-1P 477251-92-6P


477251-93-7P 477251-94-8P 477251-95-9P
 477251-97-1P 477251-99-3P 477252-00-9P
 477252-01-0P 477252-02-1P 477252-03-2P
 477252-04-3P 477252-06-5P 477252-07-6P
 477252-08-7P 477252-09-8P 477252-10-1P
 477252-11-2P 477252-13-4P 477252-14-5P
 477252-15-6P 477252-16-7P 477252-21-4P
 477252-22-5P 477252-23-6P 477252-24-7P
 477252-25-8P 477252-26-9P 477252-27-0P
 477252-28-1P 477252-30-5P 477252-31-6P
 477252-32-7P 477252-33-8P 477252-34-9P
 477252-35-0P 477252-36-1P 477252-39-4P
 477252-40-7P 477252-41-8P 477252-43-0P
 477252-64-5P 477252-65-6P 694489-50-4P
 694489-52-6P 694489-53-7P 694489-54-8P
 694489-55-9P 694489-56-0P 694489-57-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors
 of phosphodiesterase-4)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
 dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-82-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-
 propyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)



RN 477251-83-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-
 dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-85-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-87-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477251-88-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-89-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-92-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10764229




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-94-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-95-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477251-97-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-99-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-00-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-01-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-02-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-03-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-04-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-06-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-07-6 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

10764229




RN 477252-08-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-09-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-11-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-13-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-14-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-15-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-16-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-21-4 CAPLUS


10764229

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-22-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-23-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-24-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-26-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 477252-27-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-28-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-30-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-31-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-33-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-34-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-36-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-39-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-41-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-43-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 477252-64-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-65-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 694489-50-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 694489-52-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 694489-53-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 694489-54-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 694489-55-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 694489-56-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 694489-57-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3'-(1,6-dihydro-6-oxo-3-pyridinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




IT 701263-25-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(one-pot method of preparation of naphthyridine derivs. useful as inhibitors of phosphodiesterase-4)

RN 701263-25-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]- (9CI) (CA INDEX NAME)



IT 477252-46-3P 477252-47-4P 477252-48-5P
477252-49-6P 477252-50-9P 477252-51-0P
477252-53-2P 477252-54-3P 477252-55-4P

10764229

477252-56-5P 477252-57-6P 477252-58-7P

477252-59-8P 477252-60-1P 477252-61-2P


477252-62-3P 477252-63-4P 694489-58-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(one-pot preparation of naphthyridine derivs., useful as inhibitors of phosphodiesterase-4)


RN 477252-46-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 477252-47-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-48-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-50-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-51-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




10764229



RN 477252-56-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-57-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI)
(CA INDEX NAME)

10764229




RN 477252-58-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-60-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-


10764229

1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-61-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-62-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-63-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 694489-58-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:906219 CAPLUS

DOCUMENT NUMBER: 138:4594

TITLE: Preparation of 1-biaryl-[1,8]naphthyridin-4-one phosphodiesterase IV inhibitors for treatment of asthma and inflammation

INVENTOR(S): Guay, Daniel; Girard, Mario; Hamel, Pierre; Laliberte, Sebastien; Friesen, Richard; Girard, Yves; Li, Chun

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.

SOURCE: PCT Int. Appl., 166 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2002094823 | A1 | 20021128 | WO 2002-CA746 | 20020522 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


| | | | | |
|------------|----|----------|-----------------|----------|
| CA 2447765 | AA | 20021128 | CA 2002-2447765 | 20020522 |
| EP 1397359 | A1 | 20040317 | EP 2002-727127 | 20020522 |
| EP 1397359 | B1 | 20050831 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


| | | | | |
|---------------|----|----------|----------------|----------|
| JP 2004534773 | T2 | 20041118 | JP 2002-591496 | 20020522 |
| AT 303384 | E | 20050915 | AT 2002-727127 | 20020522 |
| US 2003096829 | A1 | 20030522 | US 2002-154591 | 20020524 |
| US 6677351 | B2 | 20040113 | | |

PRIORITY APPLN. INFO.: US 2001-293247P P 20010524
WO 2002-CA746 W 20020522

OTHER SOURCE(S): MARPAT 138:4594
GI



I



II


- AB Title compds. I [wherein Ar = Ph, pyridyl, pyrimidyl, indolyl, quinolinyl, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, or heteroaryl oxides; R = H or alkyl; R1 = H or (un)substituted (cyclo)alkyl, alkoxy, alkenyl, alkynyl, heteroaryl, or heterocyclyl; R2 = H, halo, (cyclo)alkyl, alkoxy, amino, acyl, alkoxycarbonyl, alkylsulfamoyl, alkylsulfonyl, or (un)substituted Ph, heteroaryl, or heterocyclyl, etc.; R3 = H, OH, NH2, halo, (un)substituted alkyl; R4-R7 = independently H, halo, NH2, or (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salts thereof] were prepared as phosphodiesterase IV (PDE4) inhibitors for the treatment of asthma and inflammation. For instance, Et 3-(3-bromoanilino)-2-(2-chloronicotinoyl)acrylate was cyclized using NaH in THF and the resulting ester saponified to give 1-(3-bromophenyl)-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid. Amidation with isopropylamine, followed by treatment with 3-acetylphenylboronic acid in the presence of trans-PdBr2(PPh3)2 and Na2CO3 in toluene and EtOH gave II. I demonstrated PDE4 inhibitory activity by suppression of TNF- α secretion in LPS stimulated human blood with IC50 values generally ranging from 0.005 μ M to 15.4 μ M. In a SPA based PDE activity assay, I inhibited the hydrolysis of cAMP to AMP by human recombinant phosphodiesterase IVa with IC50 values between 34.3 nM and 134.0 nM.
- IT **477251-93-5P**, N-Isopropyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-87-9P**, N-Isopropyl-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-91-5P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-92-6P**,

N-Isopropyl-1-[3-[4-[4-(tert-butyloxycarbonyl)piperazin-1-yl]phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-93-7P**, N-Isopropyl-1-[3-(quinolin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-95-9P**, N-Cyclopropyl-1-[3-(pyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-97-1P**, N-Isopropyl-1-[3-(5-methylthiopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-99-3P**, N-Cyclopropyl-1-[3-(4-hydroxymethylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-00-9P**, N-Cyclopropyl-1-[3-(pyridin-4-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-01-0P**, N-Cyclopropyl-1-[3-(4-ethylthiophenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-05-4P**, N-Isopropyl-1-[3-(4-methylthiophenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-07-6P**, N-Isopropyl-1-[3-(5-carboethoxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-08-7P**, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-09-8P**, N-Isopropyl-1-[3-[6-(2-methylpropyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-11-2P**, N-Isopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-23-6P**, N-Cyclopropyl-1-[3-(6-methylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-25-8P**, N-Cyclopropyl-1-[3-(5-bromopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-26-9P**, N-Cyclopropyl-1-[3-(6-benzoyloxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-31-6P**, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-32-7P**, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-35-0P**, N-Cyclopropyl-1-[3-(6-methylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-43-0P**, N-Cyclopropyl-1-[3-[5-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4 inhibitor; preparation of biaryl naphthyridinone PDE4 inhibitors by cyclization and arylation of (arylamino)-(nicotinoyl)acrylates for treatment of asthma and inflammation)

RN 477251-83-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-87-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-91-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-92-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3'-[3-[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl][1,1'-biphenyl]-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10764229




RN 477251-93-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-95-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477251-97-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylthio)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-99-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-00-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-01-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylthio)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-05-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-07-6 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[3-[3-[[[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 477252-08-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-09-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-11-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-23-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-25-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-26-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(phenylmethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 477252-31-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-32-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-35-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-43-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



- IT **477251-76-6P**, N-Isopropyl-1-[3-(3-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-80-2P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(3-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-82-4P**, N-Isopropyl-1-[3-(4-n-propylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-84-6P**, N-Isopropyl-1-[3-(2-methylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-85-7P**, N-Isopropyl-N-methyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-88-0P**, N-Isopropyl-1-[3-(indol-5-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-89-1P**, N-tert-Butyl-1-[3-(4-acetylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477251-94-8P**, N-Isopropyl-1-[3-(pyrimidin-5-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-02-1P**, N-Cyclopropyl-1-[3-(3-thienyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-03-2P**, N-Cyclopropyl-1-[3-(4-sulfamoylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-04-3P**, N-Isopropyl-1-[3-(3-ethoxyphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-06-5P**, N-Isopropyl-1-[3-(3-acetyl-4-hydroxyphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-10-1P**, N-Isopropyl-1-[3-(5-acetylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-12-3P**, N-Cyclopropyl-1-[3-(1-oxidopyrimidin-5-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-13-4P**, 1-[3-[6-(1-Hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-14-5P**, N-Isopropyl-1-[3-[4-(pyridin-3-yl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-15-6P**, N-Cyclopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-16-7P**, N-Cyclopropyl-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-17-8P**, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-18-9P**, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)pyridin-4-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-

carboxamide **477252-19-0P**, N-Cyclopropyl-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxidopyridin-4-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-21-4P**, N-Cyclopropyl-1-[3-(6-isopropylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-22-5P**, N-Cyclopropyl-1-[3-(6-methoxypyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-24-7P**, N-Cyclopropyl-1-[3-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-27-0P**, N-Cyclopropyl-1-[3-[6-dicyclopropyl(hydroxy)methyl-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-28-1P**, N-Cyclopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-30-5P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-33-8P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-34-9P**, N-Isopropyl-1-[3-(4-methylsulfonylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-36-1P**, N-Isopropyl-1-[3-(5-methylsulfonylpyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-37-2P**, N-Cyclopropyl-1-[3-(4-ethylsulfonylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-38-3P**, N-Cyclopropyl-1-[3-(4-ethylsulfinylphenyl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-39-4P**, N-Isopropyl-1-[3-[4-(1-oximidoethyl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-40-7P**, N-Isopropyl-1-[3-[4-(piperazin-1-yl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-41-8P**, N-Cyclopropyl-1-[3-[4-(methylsulfonylmethyl)phenyl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-42-9P**, N-Cyclopropyl-1-[3-(1,6-dihydro-6-oxopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-44-1P**, N-Isopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-45-2P**, N-(2,6-Dichloropyridin-4-yl)-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-46-3P**, N-Isopropyl-1-[3-(5-carboethoxy-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-47-4P**, N-Isopropyl-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-48-5P**, N-Isopropyl-1-[3-[6-(2-methylpropyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-49-6P**, N-Isopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-50-9P**, N-Cyclopropyl-1-[3-(1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-51-0P**, N-Cyclopropyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-53-2P**, N-Cyclopropyl-1-[3-(1-oxidopyridin-4-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-54-3P**, N-Cyclopropyl-1-[3-(5-bromo-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-55-4P**, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]pyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-56-5P**, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide **477252-57-6P**, N-Cyclopropyl-1-[[3-[5-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]-1-oxidopyridin-3-yl]phenyl]]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-


carboxamide **477252-58-7P**, N-Isopropyl-1-[3-(1-oxidoquinolin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-59-8P, N-Isobutyl-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-60-1P, N-Cyclopropyl-1-[3-(6-methyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-61-2P, N-Cyclopropyl-1-[3-(6-methylsulfonyl-1-oxidopyridin-3-yl)phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-62-3P, N-Cyclopropyl-1-[5-bromo-3-[6-(1-hydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-63-4P, N-Cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxidopyridin-3-yl]phenyl]-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxamide
477252-64-5P 477252-65-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of biarylnaphthyridinone PDE4 inhibitors by cyclization and arylation of (arylamino)(nicotinoyl)acrylates for treatment of asthma and inflammation)


RN 477251-76-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-80-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl[1,1'-biphenyl]-3-yl)-N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-82-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-(4'-propyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)

10764229




RN 477251-84-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-(2'-methyl[1,1'-biphenyl]-3-yl)-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-85-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-methyl-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-88-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-(1H-indol-5-yl)phenyl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477251-89-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-(4'-acetyl[1,1'-biphenyl]-3-yl)-N-(1,1-dimethylethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477251-94-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[3-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 477252-02-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-03-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[4'-(aminosulfonyl)[1,1'-biphenyl]-3-yl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-04-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-ethoxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-06-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1-(3'-acetyl-4'-hydroxy[1,1'-biphenyl]-3-yl)-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-10-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-acetyl-3-pyridinyl)phenyl]-1,4-dihydro-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-12-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-5-pyrimidinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-13-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-14-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(3-pyridinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-15-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-16-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[4-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-17-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-18-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-19-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[3-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)


10764229

NAME)




RN 477252-21-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-[(1-methylethyl)sulfonyl]-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-22-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methoxy-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-24-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-4-oxo-1-[3-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

10764229




RN 477252-27-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(dicyclopropylhydroxymethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-28-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-30-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-33-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-34-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-36-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[5-(methylsulfonyl)-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-37-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfonyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-38-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[4'-(ethylsulfinyl)[1,1'-biphenyl]-3-yl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-39-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[4'-[1-(hydroxyimino)ethyl][1,1'-biphenyl]-3-yl]-N-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-40-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-4-oxo-1-[4'-(1-piperazinyl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 477252-41-8 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[4'-[(methylsulfonyl)methyl][1,1'-biphenyl]-3-yl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-42-9 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-(1,6-dihydro-6-oxo-3-pyridinyl)phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-44-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-45-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-46-3 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[3-[3-[(1-methylethyl)amino]carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]phenyl]-, ethyl ester, 1-oxide (9CI) (CA INDEX NAME)

10764229




RN 477252-47-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[5-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(1-methylethyl)-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-48-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-[6-(2-methylpropyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477252-49-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 477252-50-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-51-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-53-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(1-oxido-4-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-54-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-(5-bromo-1-oxido-3-pyridinyl)phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-55-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1'-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



10764229


RN 477252-56-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1-oxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-57-6 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6'-(1-hydroxy-1-methylethyl)-1,1'-dioxido[3,3'-bipyridin]-5-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-58-7 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-N-(1-methylethyl)-1-[3-(1-oxido-3-quinolinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-59-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1,4-dihydro-1-[3-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-(2-methylpropyl)-4-oxo- (9CI)
(CA INDEX NAME)



RN 477252-60-1 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-(6-methyl-1-oxido-3-pyridinyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-61-2 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[6-(methylsulfonyl)-1-oxido-3-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229




RN 477252-62-3 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 1-[3-bromo-5-[6-(1-hydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-N-cyclopropyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-63-4 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1-[3-[6-(1,2-dihydroxy-1-methylethyl)-1-oxido-3-pyridinyl]phenyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 477252-64-5 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-1-oxido-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

10764229



RN 477252-65-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-1,4-dihydro-1-[3-[2-(1-hydroxy-1-methylethyl)-4-pyridinyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>